Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026

Eledon Pharmaceuticals announced that the FDA has granted Fast Track designation to its drug tegoprubart for preventing rejection in kidney transplantation. In a Phase 2 study, patients treated with tegoprubart showed a statistically significant improvement in kidney function, with a mean eGFR of 71 mL/min/1.73 m² compared to 58 mL/min/1.73 m² for those on tacrolimus at 24 months. The company plans to initiate a Phase 3 LEGACY study in the fourth quarter of 2026.